Sign in

    Simone Nasroodin

    Vice President and Equity Research Analyst at Wells Fargo

    Simone Nasroodin is a Vice President and Equity Research Analyst at Wells Fargo Securities, specializing in coverage of large-cap financial institutions including JPMorgan Chase, Bank of America, Citigroup, and Wells Fargo & Company itself. Known for her data-driven research and industry insights, she has consistently delivered investment recommendations with a success rate approaching 65% and above-average returns benchmarked on platforms such as TipRanks. Simone began her finance career in the early 2010s, previously holding roles at UBS and Jefferies before joining Wells Fargo in 2018, where she has built a reputation for sector expertise and clear communication. She holds FINRA Series 7, 63, and 86/87 licenses, is registered as a securities representative, and has been recognized for her analytical contributions in institutional client reports.

    Simone Nasroodin's questions to Apellis Pharmaceuticals (APLS) leadership

    Simone Nasroodin's questions to Apellis Pharmaceuticals (APLS) leadership • Q2 2025

    Question

    Simone Nasroodin, on for Derek Archila at Wells Fargo, requested more color on the free drug trends for Cyfovri and asked how to think about the percentage for the rest of the year, questioning if the 10-15% range mentioned last quarter is still valid.

    Answer

    EVP & Head of Global Commercial David Acheson confirmed that similar levels of free drug use are expected moving forward. He noted the $13 million revenue headwind in Q2 was a result of this usage but expressed encouragement that underlying physician and patient demand continues to drive injection growth.

    Ask Fintool Equity Research AI

    Simone Nasroodin's questions to Apellis Pharmaceuticals (APLS) leadership • Q2 2025

    Question

    Simone Nasroodin, for Derek Archila at Wells Fargo, requested more color on free drug trends for Cyfovri and asked if the 10-15% range mentioned last quarter is still a valid expectation for the rest of the year.

    Answer

    EVP of Commercial David Acheson stated that he expects similar absolute levels of free drug usage moving forward, referencing the $13 million impact in Q2. He emphasized that despite this headwind, the underlying demand from physicians and patients continues to show encouraging growth.

    Ask Fintool Equity Research AI

    Simone Nasroodin's questions to Apellis Pharmaceuticals (APLS) leadership • Q2 2025

    Question

    Simone Nasroodin from Wells Fargo asked for more color on free drug trends for Cyfovri, how to think about the percentage for the rest of the year, and if the 10-15% range mentioned last quarter is still valid.

    Answer

    EVP & Head of Global Commercial David Acheson reiterated that they expect similar levels of free drug usage moving forward, referencing the $13 million headwind in Q2. He emphasized that he is encouraged by the underlying demand at the physician and patient level, which is driving the quarter-over-quarter injection growth.

    Ask Fintool Equity Research AI

    Simone Nasroodin's questions to Apellis Pharmaceuticals (APLS) leadership • Q2 2025

    Question

    Simone Nasroodin, on for Derek Archila at Wells Fargo, requested more color on free drug trends for Cyfovri and asked if the previously guided 10-15% range for free goods was still valid for the rest of the year.

    Answer

    EVP David Acheson confirmed that Apellis expects similar levels of free drug usage moving forward, noting the $13 million headwind in Q2. He stressed that the most important takeaway is that underlying patient and physician demand continues to show healthy growth, as reflected in the injection numbers.

    Ask Fintool Equity Research AI